ICOS Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (990)	6/13/2003 3:40:22 PM
From: Icebrg	Read Replies (1) of 1139

NEW YORK, June 13 (New Ratings) - Analysts at Robert W Baird issue an "outperform" rating on ICOS Corp (ICOS). The target price has been raised from $40 to $50. The analysts mention that despite an increase of 80% in the stock price year-to-date, upside potential is still visible. The analysts say that ICOS’ 50% share in Cialis, marketed in partnership with Lilly, is on track to record $35 million in revenues from Europe alone during the current quarter. The company has already secured 30% of the market for the drug, the analysts report. [With the current share price around 43-44, he doesn't seem to be expecting much from the rest of the market].

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next